We will directly test the hypothesis that an initial strategy of lisinopril-based therapy
will be more effective than atenolol-based therapy in causing regression of left ventricular
hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar
degree of BP reduction.
Phase:
Phase 3
Details
Lead Sponsor:
Indiana University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)